New drug BNT329 targets Hard-to-Treat cancers in early trial
NCT ID NCT07186842
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 33 times
Summary
This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tumor growth, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
-
Hospital San Pedro
RECRUITINGLogroño, 26006, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario HM Sanchinarro - START Madrid CIOCC
RECRUITINGMadrid, 28050, Spain
-
Hospital Universitario Quironsalud Madrid - NEXT Oncology
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Northern Centre for Cancer Research
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
-
St. Josef-Hospital im Katholischen Klinikum Bochum
RECRUITINGBochum, 44791, Germany
-
The Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Universitaetsklinikum Ulm
RECRUITINGUlm, D-89081, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.